Safety profiles
Treatment-related adverse, neutropenia, diarrhea
ADVERSE EVENTS, REACTIVE CUTANEOUS CAPILLARY ENDOTHELIAL PROLIFERATION, NEUTROPENIA, ADVERSE EVENT
In the IP/IC plus camrelizumab group, the median cycle number was six for chemotherapy and seven for camrelizumab, respectively; while in the EP/EC plus PD-L1 inhibitor group, the median cycle number was five for chemotherapy and six for immunotherapy. The most common TRAE in the IP/IC plus camrelizumab group was neutropenia, followed by reactive cutaneous capillary endothelial proliferation (RCCEP) and diarrhea (Treatment-related adverse events.EP/EC, (etoposide plus cisplatin, or etoposide plus carboplatin); IP/IC, (irinotecan plus cisplatin, or irinotecan plus carboplatin); TRAE, treatment-related adverse event; RCCEP, reactive cutaneous capillary endothelial proliferation.Immune-related adverse events.EP/EC, (etoposide plus cisplatin, or etoposide plus carboplatin); IP/IC, (irinotecan plus cisplatin, or irinotecan plus carboplatin); irAE, immune-related adverse event; RCCEP, reactive cutaneous capillary endothelial proliferation.